Role of Wnt5a in suppressing invasiveness of hepatocellular carcinoma via epithelial‑mesenchymal transition

Wakizaka,Kazuki; Kamiyama,Toshiya; Wakayama,Kenji; Orimo,Tatsuya; Shimada,Shingo; Nagatsu,Akihisa; Kamachi,Hirofumi; Yokoo,Hideki; Fukai,Moto; Kobayashi,Nozomi; Mitsuhashi,Tomoko; Taketomi,Akinobu

doi:10.3892/ol.2020.12131

Role of Wnt5a in suppressing invasiveness of hepatocellular carcinoma via epithelial‑mesenchymal transition

Authors:
- Kazuki Wakizaka
- Toshiya Kamiyama
- Kenji Wakayama
- Tatsuya Orimo
- Shingo Shimada
- Akihisa Nagatsu
- Hirofumi Kamachi
- Hideki Yokoo
- Moto Fukai
- Nozomi Kobayashi
- Tomoko Mitsuhashi
- Akinobu Taketomi
View Affiliations

Affiliations: Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060‑8638, Japan, Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido 060‑8648, Japan
Published online on: September 21, 2020 https://doi.org/10.3892/ol.2020.12131
Article Number: 268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inappropriate activation of the canonical Wnt signaling pathway is associated with progression of hepatocellular carcinoma (HCC). However, the association between the non‑canonical pathway activated by Wnt5a and HCC is not well known. The present study investigated the significance of Wnt5a expression in HCC. Immunohistochemical staining of Wnt5a was performed on specimens from 243 patients who underwent hepatic resection for HCC. The present study investigated whether Wnt5a expression was associated with clinical and pathological factors and prognosis. Wnt5a expression in human HCC cell lines was investigated using western blotting. The effects of overexpression or knockdown of Wnt5a were evaluated using proliferation and invasion assays. Changes in epithelial‑mesenchymal transition (EMT)‑related molecules were investigated using western blotting. Wnt5a negativity was significantly associated with poor tumor differentiation and positive vascular invasion. In univariate analysis, Wnt5a negativity was identified as a significant prognostic factor for overall survival (OS). Multivariate analysis of OS demonstrated that Wnt5a negativity was an independent prognostic factor. Wnt5a expression was lower in HLE and HLF cells than in HepG2 and Huh7 cells. Knockdown of Wnt5a by short hairpin RNA transfection increased the proliferation and invasiveness of Huh7 cells, and decreased the expression levels of E‑cadherin. In HLF cells, overexpression of Wnt5a inhibited invasiveness and decreased the expression levels of vimentin. Wnt5a negativity was associated with poor tumor differentiation and positive vascular invasion, and was an independent poor prognostic factor in patients with HCC. Wnt5a may be a tumor suppressor involved in EMT‑mediated changes in invasiveness.

View Figures

View References

1	Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P and Vilgrain V: EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
2	Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Suzuki T, Shimamura T, Furukawa H, Matsushita M and Todo S: Recurrence patterns after hepatectomy of hepatocellular carcinoma: Implication of Milan criteria utilization. Ann Surg Oncol. 16:1560–1571. 2009. View Article : Google Scholar : PubMed/NCBI
3	Nusse R and Clevers H: Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
4	Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
5	Asem MS, Buechler S, Wates RB, Miller DL and Stack MS: Wnt5a signaling in cancer. Cancers (Basel). 8:792016. View Article : Google Scholar
6	van Amerongen R and Nusse R: Towards an integrated view of Wnt signaling in development. Development. 136:3205–3214. 2009. View Article : Google Scholar : PubMed/NCBI
7	Zhou Y, Kipps TJ and Zhang S: Wnt5a signaling in normal and cancer stem cells. Stem Cells Int. 2017:52952862017. View Article : Google Scholar : PubMed/NCBI
8	Kremenevskaja N, Von Wasielewski R, Rao AS, Schöfl C, Andersson T and Brabant G: Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene. 24:2144–2154. 2005. View Article : Google Scholar : PubMed/NCBI
9	Dejmek J, Dejmek A, Säfholm A, Sjölander A and Andersson T: Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 65:9142–9146. 2005. View Article : Google Scholar : PubMed/NCBI
10	Prasad CP, Chaurasiya SK, Guilmain W and Andersson T: WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. J Exp Clin Cancer Res. 35:1442016. View Article : Google Scholar : PubMed/NCBI
11	Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M and Trent JM: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 1:279–288. 2002. View Article : Google Scholar : PubMed/NCBI
12	Wang B, Tang Z, Gong H, Zhu L and Liu X: Wnt5a promotes epithelial-to-mesenchymal transition and metastasis in non-small-cell lung cancer. Biosci Rep. 37:BSR201710922017. View Article : Google Scholar : PubMed/NCBI
13	Kanzawa M, Semba S, Hara S, Itoh T and Yokozaki H: WNT5A is a key regulator of the epithelial-mesenchymal transition and cancer stem cell properties in human gastric carcinoma cells. Pathobiology. 80:235–244. 2013. View Article : Google Scholar : PubMed/NCBI
14	Jin F, Qu X, Fan Q, Wang L, Tang T, Hao Y and Dai K: Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling. Mol Med Rep. 8:1486–1492. 2013. View Article : Google Scholar : PubMed/NCBI
15	Bauer M, Bénard J, Gaasterland T, Willert K and Cappellen D: WNT5A encodes two isoforms with distinct functions in cancers. PLoS One. 8:e805262013. View Article : Google Scholar : PubMed/NCBI
16	The Liver Cancer Study Group of Japan, . The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 6th. Kanehara & Co., Ltd.; Tokyo: 2015
17	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
18	Geng M, Cao YC, Chen YJ, Jiang H, Bi LQ and Liu XH: Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol. 18:1328–1338. 2012. View Article : Google Scholar : PubMed/NCBI
19	Prgomet Z, Andersson T and Lindberg P: Higher expression of WNT5A protein in oral squamous cell carcinoma compared with dysplasia and oral mucosa with a normal appearance. Eur J Oral Sci. 125:237–246. 2017. View Article : Google Scholar : PubMed/NCBI
20	Zhong Z, Shan M, Wang J, Liu T, Shi Q and Pang D: Decreased Wnt5a expression is a poor prognostic factor in triple-negative breast cancer. Med Sci Monit. 22:1–7. 2016. View Article : Google Scholar : PubMed/NCBI
21	Kim Y, Hong M, Do IG, Ha SY, Lee D and Suh YL: Wnt5a, Ryk and Ror2 expression in glioblastoma subgroups. Pathol Res Pract. 211:963–972. 2015. View Article : Google Scholar : PubMed/NCBI
22	Cheng R, Sun B, Liu Z, Zhao X, Qi L, Li Y and Gu Q: Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition. J Cell Physiol. 229:1908–1917. 2014. View Article : Google Scholar : PubMed/NCBI
23	Liu XH, Pan MH, Lu ZF, Wu B, Rao Q, Zhou ZY and Zhou XJ: Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma. Dig Liver Dis. 40:560–567. 2008. View Article : Google Scholar : PubMed/NCBI
24	Yang SL, Luo YY, Chen M, Zhou YP, Lu FR, Deng DF and Wu YR: A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy. HPB (Oxford). 19:835–842. 2017. View Article : Google Scholar : PubMed/NCBI
25	Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, et al: Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer. 8:902009. View Article : Google Scholar : PubMed/NCBI
26	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
27	Gonzalez DM and Medici D: Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 7:re82014. View Article : Google Scholar : PubMed/NCBI
28	Xue Y, Zhang L, Zhu Y, Ke X, Wang Q and Min H: Regulation of proliferation and epithelial-to-mesenchymal transition (EMT) of gastric cancer by ZEB1 via modulating Wnt5a and related mechanisms. Med Sci Monit. 25:1663–1670. 2019. View Article : Google Scholar : PubMed/NCBI
29	Qin L, Yin YT, Zheng FJ, Peng LX, Yang CF, Bao YN, Liang YY, Li XJ, Xiang YQ, Sun R, et al: WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis. Oncotarget. 6:10239–10252. 2015. View Article : Google Scholar : PubMed/NCBI
30	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
31	Winer A, Adams S and Mignatti P: Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. Mol Cancer Ther. 17:1147–1155. 2018. View Article : Google Scholar : PubMed/NCBI